$NBY
NovaBay Pharmaceuticals Inc Stock $nby

$nby Overview Financials Valuation SEC Filings Company Website

2021 Q3 Form 10-Q Financial Statement

#000143774921019696 Filed on August 12, 2021

Income Statement

Concept	2021 Q3	2021 Q2	2020 Q2
Revenue	$1.840M	$2.133M	$3.984M
YoY Change	-15.21%	-46.46%	122.69%
Cost Of Revenue	$493.0K	$614.0K	$2.040M
YoY Change	-8.02%	-69.9%	406.2%
Gross Profit	$1.347M	$1.519M	$1.944M
YoY Change	-17.56%	-21.86%	40.26%
Gross Profit Margin	73.21%	71.21%	48.8%
Selling, General & Admin	$3.626M	$3.357M	$2.900M
YoY Change	1.54%	15.76%	6.11%
% of Gross Profit	269.19%	221.0%	149.18%
Research & Development	$10.00K	$21.00K	$115.0K
YoY Change	-92.0%	-81.74%	259.38%
% of Gross Profit	0.74%	1.38%	5.92%
Depreciation & Amortization	$13.00K	$11.00K	$14.00K
YoY Change	8.33%	-21.43%	-12.5%
% of Gross Profit	0.97%	0.72%	0.72%
Operating Expenses	$3.636M	$3.378M	$3.015M
YoY Change	-1.62%	12.04%	9.04%
Operating Profit	-$2.289M	-$1.859M	-$1.071M
YoY Change	11.01%	73.58%	-22.34%
Interest Expense	$0.00	$0.00	-$3.772M
YoY Change	-100.0%	-100.0%	232.92%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	$362.0K
YoY Change	-100.0%	-100.0%	-193.54%
Pretax Income	-$2.289M	-$1.859M	-$4.481M
YoY Change	-28.94%	-58.51%	79.31%
Income Tax	$0.00	$0.00	$1.000K
% Of Pretax Income
Net Earnings	-$2.289M	-$1.859M	-$4.482M
YoY Change	-28.94%	-58.52%	79.21%
Net Earnings / Revenue	-124.4%	-87.15%	-112.5%
Basic Earnings Per Share	-$0.05	-$0.04
Diluted Earnings Per Share	-$50.96K	-$43.68K	-$147.5K
COMMON SHARES
Basic Shares Outstanding	44.94M	42.56M	30.38M
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q3	2021 Q2	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.028M	$10.29M	$8.775M
YoY Change	-32.69%	17.31%	139.23%
Cash & Equivalents	$9.028M	$10.29M	$8.775M
Short-Term Investments
Other Short-Term Assets	$117.0K	$97.00K	$114.0K
YoY Change	51.95%	-14.91%	-54.76%
Inventory	$969.0K	$682.0K	$626.0K
Prepaid Expenses
Receivables	$843.0K	$1.232M	$1.391M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$11.50M	$12.77M	$11.91M
YoY Change	-28.2%	7.26%	58.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$96.00K	$94.00K	$84.00K
YoY Change	26.32%	11.9%	-52.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$476.0K	$475.0K	$477.0K
YoY Change	0.0%	-0.42%	-11.99%
Total Long-Term Assets	$742.0K	$831.0K	$1.364M
YoY Change	-30.65%	-39.08%	-42.54%
TOTAL ASSETS
Total Short-Term Assets	$11.50M	$12.77M	$11.91M
Total Long-Term Assets	$742.0K	$831.0K	$1.364M
Total Assets	$12.24M	$13.60M	$13.27M
YoY Change	-28.35%	2.49%	34.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.354M	$208.0K	$1.291M
YoY Change	70.1%	-83.89%	262.64%
Accrued Expenses	$1.325M	$1.883M	$1.282M
YoY Change	-19.94%	46.88%	-33.61%
Deferred Revenue	$658.0K	$904.0K	$473.0K
YoY Change	78.8%	91.12%	50.64%
Short-Term Debt	$0.00	$0.00	$522.0K
YoY Change	-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.874M	$2.389M	$4.301M
YoY Change	-4.3%	-44.45%	28.31%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$1.000K	$5.000K	$7.988M
YoY Change	-99.49%	-99.94%	3008.17%
Total Long-Term Liabilities	$1.000K	$5.000K	$7.988M
YoY Change	-99.49%	-99.94%	3008.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.874M	$2.389M	$4.301M
Total Long-Term Liabilities	$1.000K	$5.000K	$7.988M
Total Liabilities	$2.875M	$2.394M	$12.29M
YoY Change	-10.16%	-80.52%	49.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$141.7M	-$139.4M	-$131.1M
YoY Change	5.52%	6.37%	7.4%
Common Stock	$450.0K	$447.0K	$346.0K
YoY Change	7.91%	29.19%	67.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.364M	$11.21M	$983.0K
YoY Change
Total Liabilities & Shareholders Equity	$12.24M	$13.60M	$13.27M
YoY Change	-28.35%	2.49%	34.47%

Cashflow Statement

Concept	2021 Q3	2021 Q2	2020 Q2
OPERATING ACTIVITIES
Net Income	-$2.289M	-$1.859M	-$4.482M
YoY Change	-28.94%	-58.52%	79.21%
Depreciation, Depletion And Amortization	$13.00K	$11.00K	$14.00K
YoY Change	8.33%	-21.43%	-12.5%
Cash From Operating Activities	-$1.468M	-$1.987M	-$1.041M
YoY Change	7.15%	90.87%	-41.48%
INVESTING ACTIVITIES
Capital Expenditures	-$17.00K	-$2.000K	$0.00
YoY Change	240.0%		-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$17.00K	-$2.000K	$0.00
YoY Change	240.0%		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	219.0K	1.775M	4.108M
YoY Change	-96.36%	-56.79%	63.02%
NET CHANGE
Cash From Operating Activities	-1.468M	-1.987M	-1.041M
Cash From Investing Activities	-17.00K	-2.000K	0.000
Cash From Financing Activities	219.0K	1.775M	4.108M
Net Change In Cash	-1.266M	-214.0K	3.067M
YoY Change	-127.3%	-106.98%	316.71%
FREE CASH FLOW
Cash From Operating Activities	-$1.468M	-$1.987M	-$1.041M
Capital Expenditures	-$17.00K	-$2.000K	$0.00
Free Cash Flow	-$1.451M	-$1.985M	-$1.041M
YoY Change	6.3%	90.68%	-41.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44943364
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2021Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	185000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	236000	USD
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44615000
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44615000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41782000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41782000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	200000	USD
CY2021Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2020Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2020Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10294000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11952000	USD
CY2021Q2	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	1232000	USD
CY2020Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	1106000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	682000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	608000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	564000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	576000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	12772000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	14242000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	262000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	436000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	94000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	84000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	475000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	476000	USD
CY2021Q2	us-gaap	Assets Assets	13603000	USD
CY2020Q4	us-gaap	Assets Assets	15238000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	208000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	302000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1883000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2115000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	298000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	416000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2389000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2833000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	87000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	2394000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	2920000	USD
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	447000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	418000	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	150202000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	147963000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-139440000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-136063000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	11209000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	12318000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13603000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15238000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2133000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3984000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3940000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5876000	USD
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	614000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2040000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1069000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2621000	USD
CY2021Q2	us-gaap	Gross Profit GrossProfit	1519000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	1944000	USD
	us-gaap	Gross Profit GrossProfit	2871000	USD
	us-gaap	Gross Profit GrossProfit	3255000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	115000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	124000	USD
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1788000	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	362000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	176000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1859000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4481000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3377000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6063000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	USD
CY2020Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1423000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3468000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2983000	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1569000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1477000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2756000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2754000	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	3378000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	3015000	USD
	us-gaap	Operating Expenses OperatingExpenses	6250000	USD
	us-gaap	Operating Expenses OperatingExpenses	5861000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1859000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1071000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3379000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2606000	USD
CY2021Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-0	USD
CY2020Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3772000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3635000	USD
CY2021Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2020Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1859000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-4482000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3377000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6064000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2021Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42561000
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30384000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42174000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29012000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	12318000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-1518000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	130000	USD
CY2021Q1	nby	Stock Based Compensation Expense Related To Non Employee And Director Stock Options StockBasedCompensationExpenseRelatedToNonEmployeeAndDirectorStockOptions	53000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	10983000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1859000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	13000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1776000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1906000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	27000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	134000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-12000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	230000	USD
	nby	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-174000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	242000	USD
CY2021Q2	nby	Stock Based Compensation Expense Related To Non Employee And Director Stock Options StockBasedCompensationExpenseRelatedToNonEmployeeAndDirectorStockOptions	54000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	11209000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	973000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-1582000	USD
CY2020Q1	nby	Stock Issued In Connection With Exercise Of Warrants Value StockIssuedInConnectionWithExerciseOfWarrantsValue	201000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	45000	USD
CY2020Q1	nby	Stock Based Compensation Expense Related To Non Employee And Director Stock Options StockBasedCompensationExpenseRelatedToNonEmployeeAndDirectorStockOptions	12000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-349000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-4482000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5220000	USD
CY2020Q2	nby	Stock Issued In Connection With Exercise Of Warrants Value StockIssuedInConnectionWithExerciseOfWarrantsValue	468000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	92000	USD
CY2020Q2	nby	Stock Based Compensation Expense Related To Non Employee And Director Stock Options StockBasedCompensationExpenseRelatedToNonEmployeeAndDirectorStockOptions	-2000	USD
CY2020Q2	nby	Adjustments To Additional Paid In Capital Stock Option Modification AdjustmentsToAdditionalPaidInCapitalStockOptionModification	36000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	983000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3377000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6064000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	28000	USD
	nby	Share Based Compensation Expense For Stock Option Modification ShareBasedCompensationExpenseForStockOptionModification	0	USD
	nby	Share Based Compensation Expense For Stock Option Modification ShareBasedCompensationExpenseForStockOptionModification	36000	USD
	nby	Vesting Of Employee Restricted Stock Awards VestingOfEmployeeRestrictedStockAwards	-2000	USD
	nby	Vesting Of Employee Restricted Stock Awards VestingOfEmployeeRestrictedStockAwards	2000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	13000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3635000	USD
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-0	USD
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	2000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	143000	USD
	nby	Interest Expense Related To Amortization Of Debt Issuance Related To Related Party Notes Payable InterestExpenseRelatedToAmortizationOfDebtIssuanceRelatedToRelatedPartyNotesPayable	0	USD
	nby	Interest Expense Related To Amortization Of Debt Issuance Related To Related Party Notes Payable InterestExpenseRelatedToAmortizationOfDebtIssuanceRelatedToRelatedPartyNotesPayable	2000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	126000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	498000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	74000	USD
	nby	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-449000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-0	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-326000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	473000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-200000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-513000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	115000	USD
	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	0	USD
	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	73000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	432000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3406000	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	-0	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1775000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3744000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1775000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5220000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	669000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	-0	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1145000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1658000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1838000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12427000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7412000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10769000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9250000	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	55000	USD
	nby	Related Party Loan Interest Paid Via Accounts Receivable RelatedPartyLoanInterestPaidViaAccountsReceivable	0	USD
	nby	Related Party Loan Interest Paid Via Accounts Receivable RelatedPartyLoanInterestPaidViaAccountsReceivable	173000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Use of Estimates </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include contract liabilities related to product sales, useful lives for property and equipment and related depreciation calculations, assumptions for valuing options and warrants, income taxes and other contingencies. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10294000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11952000	USD
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	475000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	475000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10769000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12427000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Concentrations of Credit Risk and Major Partners</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a highly-rated, major financial institution in the United States. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Deposits in this bank <em style="font: inherit;"> may </em>exceed the amount of federal insurance provided on such deposits. The Company does <em style="font: inherit;">not</em> believe it is exposed to significant credit risk due to the financial position of the financial institution in which the deposits are held. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">During the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2021, </em>Company revenues were derived primarily from sales of Avenova. During the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020, </em>revenues were derived primarily from sales of <em style="font: inherit;">KN95</em> Masks and Avenova.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">During the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2021 </em>and <em style="font: inherit;">2020,</em> revenues from each product were as follows (in thousands):</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended June 30,</b></b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Six Months Ended June 30,</b></b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Avenova</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,883</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,140</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">3,458</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2,686</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">KN95 Masks</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2,839</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,012</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">NeutroPhase</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">173</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other products</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">68</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">294</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total product revenue, net</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2,126</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,979</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,927</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">5,871</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other revenue, net</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total sales, net</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,133</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,984</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,940</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,876</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2021 </em>and <em style="font: inherit;">2020,</em> sales of Avenova via Amazon comprised 52% and 42% of total Avenova net revenue, respectively. During the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2021 </em>and <em style="font: inherit;">2020,</em> sales of Avenova via Amazon comprised 58% and 46% of total Avenova net revenue, respectively. <em style="font: inherit;">No</em> other individual distributor comprised greater than <em style="font: inherit;">10%</em> of total Avenova net revenue during the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2021 </em>and <em style="font: inherit;">2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> June 30, 2021 </em>and <em style="font: inherit;"> December 31, 2020, </em>accounts receivable from our major distribution partners greater than <em style="font: inherit;">10%</em> were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>June 30,</b></b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 66%; border-bottom: 3px solid black;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Major distribution partner</b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;">Distributor C</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">29</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Distributor A</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">18</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;">CVS</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Avenova Direct via Amazon</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">11</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Congqing Pioneer Pharma Holdings Limited</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;">Distributor B</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">14</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">* Less than <em style="font: inherit;">10%</em> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company relies on <em style="font: inherit;">two</em> contract manufacturers to produce its products. The Company does <em style="font: inherit;">not</em> own any manufacturing facilities and intends to continue to rely on <em style="font: inherit;">third</em> parties for the supply of finished goods. Contract manufacturers <em style="font: inherit;"> may </em>or <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be able to meet the Company’s needs with respect to timing, quantity or quality. In particular, it is possible that we <em style="font: inherit;"> may </em>suffer from unexpected supply chain delays in light of the ongoing COVID-<em style="font: inherit;">19</em> pandemic.</p>
CY2021Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2133000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3984000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3940000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5876000	USD
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2021Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	200000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29012000
CY2021Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2021Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42561000
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30384000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42174000
CY2021Q2	us-gaap	Advertising Expense AdvertisingExpense	700000	USD
CY2020Q2	us-gaap	Advertising Expense AdvertisingExpense	300000	USD
	us-gaap	Advertising Expense AdvertisingExpense	1500000	USD
	us-gaap	Advertising Expense AdvertisingExpense	700000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1859000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-4482000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3377000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6064000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10955000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9797000
CY2021Q2	us-gaap	Prepaid Insurance PrepaidInsurance	168000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	165000	USD
CY2021Q2	nby	Prepaid Inventory PrepaidInventory	104000	USD
CY2020Q4	nby	Prepaid Inventory PrepaidInventory	0	USD
CY2021Q2	nby	Prepaid Financing Cost Current PrepaidFinancingCostCurrent	68000	USD
CY2020Q4	nby	Prepaid Financing Cost Current PrepaidFinancingCostCurrent	0	USD
CY2021Q2	nby	Prepaid Due And Subscriptions PrepaidDueAndSubscriptions	54000	USD
CY2020Q4	nby	Prepaid Due And Subscriptions PrepaidDueAndSubscriptions	53000	USD
CY2021Q2	nby	Prepaid Sales Rebate PrepaidSalesRebate	42000	USD
CY2020Q4	nby	Prepaid Sales Rebate PrepaidSalesRebate	144000	USD
CY2021Q2	nby	Prepaid Patents PrepaidPatents	31000	USD
CY2020Q4	nby	Prepaid Patents PrepaidPatents	47000	USD
CY2021Q2	nby	Prepaid Security Deposit For Lease PrepaidSecurityDepositForLease	0	USD
CY2020Q4	nby	Prepaid Security Deposit For Lease PrepaidSecurityDepositForLease	65000	USD
CY2021Q2	us-gaap	Other Assets Current OtherAssetsCurrent	97000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	102000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	564000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	576000	USD
CY2021Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	294000	USD
CY2020Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	159000	USD
CY2021Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	573000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	685000	USD
CY2021Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	185000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	236000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	682000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	608000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	716000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	686000	USD
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	622000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	602000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	94000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	84000	USD
CY2021Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11000	USD
CY2020Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	28000	USD
CY2021Q2	nby	Contract With Customer Accrued Liabilities Current ContractWithCustomerAccruedLiabilitiesCurrent	943000	USD
CY2020Q4	nby	Contract With Customer Accrued Liabilities Current ContractWithCustomerAccruedLiabilitiesCurrent	730000	USD
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	421000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	632000	USD
CY2021Q2	nby	Accrued Consulting Service Current AccruedConsultingServiceCurrent	208000	USD
CY2020Q4	nby	Accrued Consulting Service Current AccruedConsultingServiceCurrent	98000	USD
CY2021Q2	nby	Accrued Inventory Current AccruedInventoryCurrent	121000	USD
CY2020Q4	nby	Accrued Inventory Current AccruedInventoryCurrent	181000	USD
CY2021Q2	nby	Accrued Sublease Security Deposit Current AccruedSubleaseSecurityDepositCurrent	0	USD
CY2020Q4	nby	Accrued Sublease Security Deposit Current AccruedSubleaseSecurityDepositCurrent	198000	USD
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	190000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	276000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1883000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2115000	USD
CY2021Q2	us-gaap	Proceeds From Legal Settlements ProceedsFromLegalSettlements	300000	USD
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	99000	USD
CY2020Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	250000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	199000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	514000	USD
CY2021Q2	us-gaap	Sublease Income SubleaseIncome	-0	USD
CY2020Q2	us-gaap	Sublease Income SubleaseIncome	158000	USD
	us-gaap	Sublease Income SubleaseIncome	-0	USD
	us-gaap	Sublease Income SubleaseIncome	316000	USD
CY2021Q2	us-gaap	Lease Cost LeaseCost	99000	USD
CY2021Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	113000	USD
CY2020Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	284000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	226000	USD
CY2020Q2	us-gaap	Lease Cost LeaseCost	92000	USD
	us-gaap	Lease Cost LeaseCost	199000	USD
	us-gaap	Lease Cost LeaseCost	198000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	580000	USD
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y8M12D
CY2020Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y4M24D
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2020Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	228000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	89000	USD
CY2021Q2	nby	Lessee Operating Lease Liability Payments Due After Year One LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne	0	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	317000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	14000	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	303000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	298000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5000	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	303000	USD
CY2020Q2	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	0	USD
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	2000	USD
CY2021Q2	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	0	USD
CY2021Q2	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice	1.59
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6800000	USD
CY2020Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	200000	USD
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7067000
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.63
	nby	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	15000
	nby	Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice	0.67
	nby	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	-0
	nby	Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice	0
	nby	Class Of Warrant Or Right Forfeited During Period ClassOfWarrantOrRightForfeitedDuringPeriod	-0
	nby	Class Of Warrant Or Right Forfeited During Period Weighted Average Exercise Price ClassOfWarrantOrRightForfeitedDuringPeriodWeightedAverageExercisePrice	0
CY2021Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7082000
CY2021Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.63
CY2020Q4	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding	3165000
CY2020Q4	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice	2.05
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	189000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	92000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.94
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	900
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	124000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.19
CY2021Q2	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding	3873000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	296000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	126000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	479000	USD
CY2021Q2	nby	Contract With Customer Liability Deferred Revenue Current ContractWithCustomerLiabilityDeferredRevenueCurrent	2000	USD
CY2020Q4	nby	Contract With Customer Liability Product Contracts Current ContractWithCustomerLiabilityProductContractsCurrent	573000	USD
	nby	Contract With Customer Liability Product Distribution Current Additions ContractWithCustomerLiabilityProductDistributionCurrentAdditions	923000	USD
	nby	Contract With Customer Liability Product Distribution Current Deductions ContractWithCustomerLiabilityProductDistributionCurrentDeductions	594000	USD
CY2021Q2	nby	Contract With Customer Liability Product Contracts Current ContractWithCustomerLiabilityProductContractsCurrent	902000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	575000	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	669000	USD
CY2021Q2	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingNumber	3480000
CY2021Q2	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.69
	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm	P7Y7M6D
CY2021Q2	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	593000	USD
CY2021Q2	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedInPeriod	1564000
CY2021Q2	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedInPeriodWeightedAverageGrantDateFairValue	3.06
	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedWeightedAverageRemainingContractualTerm	P5Y3M18D
CY2021Q2	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAggregateIntrinsicValue	37000	USD
CY2021Q2	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Number ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableNumber	1564000
CY2021Q2	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageExercisePrice	3.06
	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageRemainingContractualTerm	P5Y3M18D
CY2021Q2	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Aggregate Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableAggregateIntrinsicValue	37000	USD
CY2021Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2021Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	183000	USD
CY2020Q4	nby	Contract With Customer Liability Deferred Revenue Current ContractWithCustomerLiabilityDeferredRevenueCurrent	2000	USD
	nby	Contract With Customer Liability Deferred Revenue Current Additions ContractWithCustomerLiabilityDeferredRevenueCurrentAdditions	2000	USD
	nby	Contract With Customer Liability Deferred Revenue Current Deductions ContractWithCustomerLiabilityDeferredRevenueCurrentDeductions	2000	USD
	nby	Contract With Customer Liability Current Additions ContractWithCustomerLiabilityCurrentAdditions	925000	USD
	nby	Contract With Customer Liability Current Deductions ContractWithCustomerLiabilityCurrentDeductions	596000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	904000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3940000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5876000	USD
CY2021Q2	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	175000	USD
CY2020Q2	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	0	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	175000	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	173000	USD
CY2021Q2	us-gaap	Related Party Costs RelatedPartyCosts	131000	USD
CY2020Q2	us-gaap	Related Party Costs RelatedPartyCosts	0	USD
	us-gaap	Related Party Costs RelatedPartyCosts	131000	USD
	us-gaap	Related Party Costs RelatedPartyCosts	90000	USD
CY2021Q2	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	100000	USD
CY2020Q4	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	200000	USD
CY2021Q2	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	10000	USD
CY2020Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	8000	USD
CY2021Q2	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	0	USD
CY2020Q2	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	29000	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	0	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	91000	USD

Files In Submission

Name	View Source	Status
0001437749-21-019696-index-headers.html	Edgar Link	pending
0001437749-21-019696-index.html	Edgar Link	pending
0001437749-21-019696.txt	Edgar Link	pending
0001437749-21-019696-xbrl.zip	Edgar Link	pending
ex_272936.htm	Edgar Link	pending
ex_272937.htm	Edgar Link	pending
ex_272938.htm	Edgar Link	pending
ex_272939.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nby-20210630.xsd	Edgar Link	pending
nby-20210630_cal.xml	Edgar Link	unprocessable
nby-20210630_def.xml	Edgar Link	unprocessable
nby-20210630_lab.xml	Edgar Link	unprocessable
nby-20210630_pre.xml	Edgar Link	unprocessable
nby20210630_10q.htm	Edgar Link	pending
nby20210630_10q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NBY
NovaBay Pharmaceuticals Inc Stock $nby

2021 Q3 Form 10-Q Financial Statement

#000143774921019696 Filed on August 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBY NovaBay Pharmaceuticals Inc Stock $nby

2021 Q3 Form 10-Q Financial Statement

#000143774921019696 Filed on August 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBY
NovaBay Pharmaceuticals Inc Stock $nby